en · de · es
ghk-cu-notes.peptides1126.com › News › Molecular Identity And Discovery Background — Evidence Review

Molecular Identity And Discovery Background — Evidence Review

By Editorial Desk · published 2025-12-17 · last reviewed 2026-01-14 · News

copper coordination raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.

Molecular Identity and Discovery Background

The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.

GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.

Handling, Stability, and Analytical Verification

Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.

Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.

Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.

Ghk-cu at a glance

PropertyValueNotes
INCI nameCopper tripeptide-1Standard designation on cosmetic ingredient labels
Peptide sequenceGly-His-LysThree-residue ligand; binding occurs at the histidine side chain
Metal-to-peptide ratio1 to 1One copper(II) ion per peptide unit
AppearanceBlue to violet powderColour arises from copper-to-peptide electronic transitions
Water solubilityFreely solubleCommonly formulated in aqueous or water-alcohol systems

Stability, Handling, and Measurement

Practical handling notes centre on limiting exposure to water, oxygen, and repeated temperature cycling. Weighed powder is often equilibrated to room temperature before opening to avoid condensation on the solid. Working solutions are typically divided into single-use aliquots and frozen rather than stored refrigerated for long periods. Reported shelf lives vary widely between laboratories, and no single set of conditions is universally treated as a reference standard, which complicates direct comparison of published stability figures.

Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.

Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.

Related pages on this site

Background and Chemical Identity

Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.

The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.

Stability, Handling, and Analytical Checks

Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.

Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.

Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.

Supporting material

Galanin-like peptide (GALP) is a neuropeptide present in humans and other mammals. It is a 60-amino acid polypeptide produced in the arcuate nucleus of the hypothalamus and the posterior pituitary gland. It is involved in the regulation of appetite and may also have other roles such as in inflammation, sex behavior, and stress. Findings additionally suggest that GALP could play a function in energy metabolism due to its ability to maintain continual activation of the sympathetic nervous system (SNS) via thermogenesis, which refers to the production of heat within living organisms. In addition, the administration of GALP directly into the brain leads to a reduction in the secretion of thyroid-stimulating hormone (TSH), which indicates the involvement of GALP in the neuroendocrine regulation of the hypothalamic-pituitary-thyroid (HPT) axis, and further adding to the evidence of the role of GALP in energy homeostasis.

=== Development === Developmentally, the majority of mucous membranes are of endodermal origin. Exceptions include the palate, cheeks, floor of the mouth, gums, lips and the portion of the anal canal below the pectinate line, which are all ectodermal in origin.

==== Regulation in β cells ==== Glucose immediately amplifies glucokinase activity by the cooperativity effect. A second important rapid regulator of glucokinase activity in β cells occurs by direct protein-protein interaction between glucokinase and the "bifunctional enzyme" (phosphofructokinase-2/fructose-2,6-bisphosphatase), which also plays a role in the regulation of glycolysis. This physical association stabilizes glucokinase in a catalytically favorable conformation (somewhat opposite the effect of GKRP binding) that enhances its activity. In as little as 15 minutes, glucose can stimulate GCK transcription and glucokinase synthesis by way of insulin. Insulin is produced by the beta cells, but some of it acts on β cell B-type insulin receptors, providing an autocrine positive-feedback amplification of glucokinase activity. Further amplification occurs by insulin action (via A-type receptors) to stimulate its own transcription. Transcription of the GCK gene is initiated through the "upstream," or neuroendocrine, promoter. This promoter, in contrast to the liver promoter, has elements homologous to other insulin-induced gene promoters. Among the probable transacting factors are Pdx-1 and PPARγ. Pdx-1 is a homeodomain transcription factor involved in the differentiation of the pancreas. PPARγ is a nuclear receptor that responds to glitazone drugs by enhancing insulin sensitivity.

=== Mortality === Published studies on the survival of Sjögren's disease patients have been limited in various respects, perhaps owing to the relatively small sample sizes and the fact that secondary Sjögren's disease is associated with other autoimmune diseases. A 2010 study found a slight increase in mortality rates of Sjögren's patients compared with the remainder of the population. A 2016 study found that primary Sjögren's was not associated with an increase in all-cause mortality as compared with the general population, but that a subset of patients with extraglandular involvement, vasculitis, hypocomplementaemia, and cryoglobulinaemia may be at increased risk of mortality. A 2021 metaanalysis showed a 46% increase in mortality, with significantly greater mortality risk in patients with older age, male gender, vasculitis, interstitial lung disease, low complements, positive anti-La/SSB and cryoglobulinaemia. Among those without other autoimmune disorders, life expectancy is unchanged.

Natural uranium (NU or Unat) is uranium with the same isotopic ratio as found in nature. It contains 0.711% uranium-235, 99.284% uranium-238, and a trace of uranium-234 by weight (0.0055%). Approximately 2.2% of its radioactivity comes from uranium-235, 48.6% from uranium-238, and 49.2% from uranium-234. Natural uranium can be used to fuel both low- and high-power nuclear reactors. Historically, graphite-moderated reactors and heavy water-moderated reactors have been fueled with natural uranium in the pure metal (U) or uranium dioxide (UO2) ceramic forms. However, experimental fuelings with uranium trioxide (UO3) and triuranium octaoxide (U3O8) have shown promise. The 0.72% uranium-235 is not sufficient to produce a self-sustaining critical chain reaction in light water reactors or nuclear weapons; these applications must use enriched uranium. Nuclear weapons take a concentration of 90% uranium-235, and light water reactors require a concentration of roughly 3% uranium-235. Unenriched natural uranium is appropriate fuel for a heavy-water reactor, like a CANDU reactor. On rare occasions, earlier in geologic history, when uranium-235 was more abundant, uranium ore was found to have naturally engaged in fission, forming natural nuclear fission reactors. Uranium-235 decays at a faster rate (half-life of 700 million years) compared to uranium-238, which decays extremely slowly (half-life of 4.5 billion years). Therefore, a billion years ago, there was more than double the uranium-235 compared to now.

Sources: en.wikipedia.org

Notes from published material

An oxytocin receptor agonist is a compound that acts as an agonist of the oxytocin receptor. They include peptides like oxytocin and carbetocin and small-molecules like LIT-001 and LIT-002. Peptide oxytocin receptor agonists are used medically to induce labor, promote lactation, and for certain other uses. Oxytocin receptor agonists are of theoretical interest for the potential treatment of neuropsychiatric disorders with social symptoms, such as autism, social anxiety, and psychopathy. Small-molecule oxytocin receptor agonists are considered to be more promising for such uses due to better potential pharmacokinetic profiles, such as blood–brain barrier permeability, elimination half-lives, and oral bioavailability. The entactogen MDMA robustly increases oxytocin levels, by 4- to 8-fold, and this is thought to be involved in its entactogenic effects, including its euphoric, anxiolytic, and prosocial effects. In people with arginine vasopressin deficiency (central diabetes insipidus), who also have oxytocin deficiency, MDMA fails to elevate oxytocin levels and shows greatly blunted entactogenic effects. Accordingly, carbetocin partially substitutes for MDMA in drug discrimination tests in rodents, whereas the peptide oxytocin receptor antagonist atosiban interfered with MDMA discrimination. In addition, oxytocin receptor antagonists have been found to block the prosocial effects of MDMA in rodents. Social isolation has been found to decrease oxytocin receptor levels in rodents, whereas levels of oxytocin were unchanged.

lipid Any of a heterogeneous class of organic compounds, including glycerides (fats), waxes, sterols, and some vitamins, united only by their amphipathic or hydrophobic nature and consequently their very low solubility in water. Some lipids such as phospholipids tend to form lamellar structures or micelles in aqueous environments, where they serve as the primary constituents of biological membranes. Others such as fatty acids can be metabolized for energy, have important functions in energy storage, or serve as signaling molecules. Colloquially, the term "lipids" is sometimes used as a synonym for fats, though fats are more correctly considered a subclass of lipids.

=== Final offensives, Kissinger's appeals to congress === On 1 March 1975, the PAVN launched a major offensive that saw them quickly overrunning the Central Highlands; by 25 March, Hue had fallen. Thiệu was slow to withdraw his divisions, and by 30 March, when Da Nang fell, the ARVN's best divisions were lost, leaving the road to Saigon wide open. It was imperative for the North Vietnamese to take Saigon before the monsoons began in May, leading to a rapid march on the city. Kissinger resisted pressure from the Joint Chiefs of Staff and the Defense Secretary, James Schlesinger, to immediately withdraw American civilians from South Vietnam, arguing it would damage South Vietnamese morale. Despite this position, Kissinger advised President Ford not to have the U.S.A.F. bomb the advancing PAVN forces, saying, "If you do that, the American people will take to the streets again". He expressed little sympathy with South Vietnam, saying: "Why don't those people die faster? The worse thing that could happen would be for them to linger on". On 15 April 1975, with the PAVN rapidly advancing, Kissinger testified before the Senate Appropriations Committee, urging Congress to increase military aid to South Vietnam by another $700 million, which was refused. Kissinger maintained at the time, and continued to maintain until his death, that if Congress had approved this request, South Vietnam would have been saved. In opposition, Karnow argued that by this point, South Vietnam was too far gone, the ARVN's morale had collapsed and it was very doubtful that anything short of sending U.S.

==== Other parameters ==== Advanced hematology analyzers generate novel measurements of blood cells which have shown diagnostic significance in research studies but have not yet found widespread clinical use. For example, some types of analyzers produce coordinate readings indicating the size and position of each white blood cell cluster. These parameters (termed cell population data) have been studied as potential markers for blood disorders, bacterial infections and malaria. Analyzers that use myeloperoxidase staining to produce differential counts can measure white blood cells' expression of the enzyme, which is altered in various disorders. Some instruments can report the percentage of red blood cells that are hypochromic in addition to reporting the average MCHC value, or provide a count of fragmented red cells (schistocytes), which occur in some types of hemolytic anemia. Because these parameters are often specific to particular brands of analyzers, it is difficult for laboratories to interpret and compare results.

Arketamine (developmental code names PCN-101, HR-071603), also known as (R)-ketamine or (R)-(−)-ketamine, is the (R)-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the (S)-(+) enantiomer of ketamine, arketamine is biologically active; however, it is less potent as an NMDA receptor antagonist and anesthetic and thus has never been approved or marketed for clinical use as an enantiopure drug. Arketamine is currently in clinical development as a novel antidepressant. Relative to esketamine, arketamine possesses 4 to 5 times lower affinity for the PCP site of the NMDA receptor. In accordance, arketamine is significantly less potent than racemic ketamine and especially esketamine in terms of anesthetic, analgesic, and sedative-hypnotic effects. Racemic ketamine has weak affinity for the sigma receptor, where it acts as an agonist, whereas esketamine binds negligibly to this receptor, and so the sigma receptor activity of racemic ketamine lies in arketamine. It was suggested that this action of arketamine may play a role in the hallucinogenic effects of racemic ketamine and that it may be responsible for the lowering of the seizure threshold seen with racemic ketamine. However several subsequent studies have indicated that esketamine is more likely to induce dissociative events, while studies in patients undergoing electroconvulsive therapy suggested that esketamine is a potent inducer of seizures.

Sources: en.wikipedia.org

Frequently asked questions

What is GHK-Cu made of?

It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.

When was GHK-Cu first described?

The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.

Is GHK-Cu the same as copper tripeptide-1?

Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.

How should GHK-Cu powder be stored?

Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.

Network